Table 3.
NLP-identified reasons for statin nonuse in patients with ASCVD, stratified by type of ASCVD and race/ethnicity.
| Cohort (N = 3929) | Reason for nonuse | p value | ||||
|---|---|---|---|---|---|---|
| Side effect | ||||||
| Muscle | Other | Nonspecific | Perceived lipid control | Patient preference | ||
| Total number | 385 | 404 | 1011 | 274 | 321 | |
| Stratified by type of ASCVD (N, % by column) | ||||||
| Coronary artery disease | 224 (58.2) | 233 (57.7) | 472 (46.7) | 123 (44.9) | 175 (54.5) | <0.001 |
| Peripheral artery disease | 35 (9.1) | 38 (9.4) | 129 (12.8) | 29 (10.6) | 47 (14.6) | |
| Cerebrovascular disease | 87 (22.6) | 85 (21.0) | 310 (30.7) | 95 (34.7) | 74 (23.1) | |
| Polyvascular disease | 39 (10.1) | 48 (11.9) | 100 (9.9) | 29 (10.6) | 47 (14.6) | |
| Stratified by race/ethnicity (N, % by column) | ||||||
| Non-Hispanic White | 244 (63.4) | 273 (67.6) | 554 (54.8) | 132 (48.2) | 214 (66.7) | <0.001 |
| Non-Hispanic Black | 13 (3.4) | 25 (6.2) | 62 (6.1) | 19 (6.9) | 13 (4.0) | |
| Hispanic | 30 (7.8) | 15 (3.7) | 96 (9.5) | 34 (12.4) | 19 (5.9) | |
| Non-Hispanic Asian | 40 (10.4) | 46 (11.4) | 96 (9.5) | 34 (12.4) | 19 (5.9) | |
ASCVD atherosclerotic cardiovascular disease, NLP natural language processing.